Daré Bioscience wins US patent for topical lopinavir-ritonavir formulation
DARE•Daré Bioscience secured U.S. Patent No. 12,678,439 covering topical lopinavir-ritonavir formulations for HPV-related cervical disorders, with protection expected to extend into at least 2039.
1. Patent and trial
The patent covers formulations for Daré’s investigational DARE-HPV vaginal insert program. The program is in a Phase 2 trial involving about 100 women, with topline results expected in 2027.
2. Program funding
Funding includes about $10 million from ARPA-H and a $2 million NIAID award.
